Evidence map›Paper›PMID 24247483›Full record

Observational studyJAMA2014

Calcium density of coronary artery plaque and risk of incident cardiovascular events.

Michael H Criqui, Julie O Denenberg, Joachim H Ix, Robyn L McClelland, Christina L Wassel, Dena E Rifkin, Jeffrey J Carr, Matthew J Budoff, Matthew A Allison

Erratum issued Registry-linked trialOpen access · greenAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in JAMA, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02418884 (The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus), which is not on this map. Cited by 324 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
324citing papers in PubMed, 2 pooled it
33.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02418884 phase4unknown statusstarted 2015, after this paper: background citation

The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus

Ran2015Enrolled122Registered outcomes3Posted comparisons0ConditionsCoronary Artery DiseaseArmsRosuvastatin
Open the trial in the graph
3 · Its place in the literature

Who cites it

324 citing papers in PubMed, 2 syntheses or guidelines pooled it, 632 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

264 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Michael H CriquiDepartment of Family and Preventive Medicine, University of California, San Diego, La Jolla2Department of Medicine, University of California, San Diego, La Jolla.
Julie O DenenbergDepartment of Family and Preventive Medicine, University of California, San Diego, La Jolla.
Joachim H IxDepartment of Medicine, University of California, San Diego, La Jolla.
Robyn L McClellandDepartment of Biostatistics, University of Washington, Seattle.
Christina L WasselDepartment of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Dena E RifkinDepartment of Medicine, University of California, San Diego, La Jolla.
Jeffrey J CarrDepartment of Radiology and Radiological Sciences, Vanderbilt University, Nashville, Tennessee.
Matthew J BudoffDivision of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles.
Matthew A AllisonDepartment of Family and Preventive Medicine, University of California, San Diego, La Jolla.
University of California, San Diego · USThe Lundquist Institute · USUniversity of Pittsburgh · USUniversity of Washington · USVanderbilt University · US

Funding

Cigarette Smoke and Susceptibility to Influenza InfectionR01HL095163 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JASPERS, ILONA, NOAH, TERRY L · 2009 to 2013
$2.0M
Adjunctive Use of Apyrase to Fibrinolytic TherapyR44HL095169 · NHLBI · APT THERAPEUTICS, INC. · PI CHEN, RIDONG · 2012 to 2013
$1.3M
Ambulatory BP, kidney function, cognitive & physical function in older adultsK23DK091521 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RIFKIN, DENA EVETTE · 2011 to 2015
$891k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY-FIELD CENTERN01HC095162 · HC · JOHNS HOPKINS UNIVERSITY · PI SZKLO, MOYSES A · 1999 to 2000
$694k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095161 · HC · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEA, STEVEN · 1999 to 2001
$642k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095165 · HC · WAKE FOREST UNIVERSITY · PI BURKE, GREGORY L · 1999 to 2001
$616k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095160 · HC · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SAAD, MOHAMMED F · 1999 to 2001
$592k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY-FIELD CENTERN01HC095164 · HC · NORTHWESTERN UNIVERSITY · PI LIU, KIANG JOHN · 1999 to 2001
$511k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095163 · HC · UNIVERSITY OF MINNESOTA TWIN CITIES · PI FOLSOM, AARON R · 1999 to 2001
$443k
Enhancing immune reconstitution after implantation of postnatal allogeneic thymusR21HL095165 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CROOKS, GAY M · 2008 to 2009
$440k
SUBCLINICAL CARDIOVASCULAR DISEASE COORDINATING CENTER-N01HC95159-268095159N01HC095159 · HC · UNIVERSITY OF WASHINGTON · PI KRONMAL, RICHARD A · 1999 to 2006
$304k
Adjunctive Use of Apyrase to Fibrinolytic TherapyR43HL095169 · NHLBI · APT THERAPEUTICS, INC. · PI CHEN, RIDONG · 2009 to 2009
$226k
NHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095160NHLBI NIH HHS N01 HC095161NHLBI NIH HHS N01 HC095162NHLBI NIH HHS N01 HC095163NHLBI NIH HHS N01 HC095164NHLBI NIH HHS N01 HC095165NHLBI NIH HHS N01 HC095169NHLBI NIH HHS N01-HC-95159NHLBI NIH HHS N01-HC-95160NHLBI NIH HHS N01-HC-95161NHLBI NIH HHS N01-HC-95162NHLBI NIH HHS N01-HC-95163NHLBI NIH HHS N01-HC-95164NHLBI NIH HHS N01-HC-95165NHLBI NIH HHS N01-HC-95169NIDDK NIH HHS K23 DK091521
6 · The paper itself

Abstract

importanceCoronary artery calcium (CAC), measured by computed tomography (CT), has strong predictive value for incident cardiovascular disease (CVD) events. The standard CAC score is the Agatston, which is weighted upward for greater calcium density. However, some data suggest increased plaque calcium density may be protective for CVD.

objectiveTo determine the independent associations of CAC volume and CAC density with incident CVD events. DESIGN, SETTING, AND

participantsMulticenter, prospective observational MESA study (Multi-Ethnic Study of Atherosclerosis), conducted at 6 US field centers of 3398 men and women from 4 race/ethnicity groups; non-Hispanic white, African American, Hispanic, and Chinese. Participants were aged 45-84 years, free of known CVD at baseline, had CAC greater than 0 on their baseline CT, and were followed up through October 2010. MAIN OUTCOMES AND MEASURES: Incident coronary heart disease (CHD) and all CVD events

resultsDuring a median of 7.6 years of follow-up, there were 175 CHD events and an additional 90 other CVD events for a total of 265 CVD events. With both lnCAC volume and CAC density scores in the same multivariable model, the lnCAC volume score showed an independent association with incident CHD, with a hazard ratio (HR) of 1.81 (95% CI, 1.47-2.23) per standard deviation (SD = 1.6) increase, absolute risk increase 6.1 per 1000 person-years, and for CVD an HR of 1.68 (95% CI, 1.42-1.98) per SD increase, absolute risk increase 7.9 per 1000 person-years. Conversely, the CAC density score showed an independent inverse association, with an HR of 0.73 (95% CI, 0.58-0.91) per SD (SD = 0.7) increase for CHD, absolute risk decrease 5.5 per 1000 person-years, and an HR of 0.71 (95% CI, 0.60-0.85) per SD increase for CVD, absolute risk decrease 8.2 per 1000 person years. Area under the receiver operating characteristic curve analyses showed significantly improved risk prediction with the addition of the density score to a model containing the volume score for both CHD and CVD. In the intermediate CVD risk group, the area under the curve for CVD increased from 0.53 (95% CI, 0.48-0.59) to 0.59 (95% CI, 0.54-0.64), P = .02. CONCLUSIONS AND RELEVANCE: CAC volume was positively and independently associated with CHD and CVD risk. At any level of CAC volume, CAC density was inversely and significantly associated with CHD and CVD risk. The role of CAC density should be considered when evaluating current CAC scoring systems.

Indexed as

AgedAged, 80 and overAtherosclerosisCalciumCoronary DiseaseCoronary VesselsFemaleHumansMaleMiddle AgedPlaque, AtheroscleroticPredictive Value of TestsProspective StudiesReference ValuesRiskTomography, X-Ray ComputedCalcium

Identifiers

PMID24247483
PMCPMC4091626
OpenAlexW2014951154

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.